{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:36:39Z","timestamp":1788572199597,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":3004,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["478923\/2007-4"],"award-info":[{"award-number":["478923\/2007-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funda\u00e7\u00e3o de Amparo a Pesquisa do Estado de Minas Gerais","award":["PPM 328-08"],"award-info":[{"award-number":["PPM 328-08"]}]},{"name":"Coordenadoria de Aperfei\u00e7oamento do Ensino Superior","award":["BEX 1199-09-9"],"award-info":[{"award-number":["BEX 1199-09-9"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1093\/annonc\/mdq715","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T20:46:52Z","timestamp":1297370812000},"page":"2073-2079","source":"Crossref","is-referenced-by-count":73,"title":["Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"22","author":[{"given":"M.S.","family":"Marcolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.D.","family":"Clementino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.V.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Marx-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.C.R.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Akkerhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq715_bb0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00280-005-1031-2","article-title":"Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study","volume":"56","author":"Pappas","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdq715_bb0015","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq715_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2006\/434761","article-title":"Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment","volume":"20","author":"Blackstein","year":"2006","journal-title":"Can J Gastroenterol"},{"key":"10.1093\/annonc\/mdq715_bb0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodelling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq715_bb0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1093\/annonc\/mdq715_bb0035","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1345\/aph.1G131","article-title":"Acute renal failure secondary to imatinib mesylate treatment in prostate cancer","volume":"39","author":"Foringer","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1093\/annonc\/mdq715_bb0040","doi-asserted-by":"crossref","first-page":"82012","DOI":"10.1155\/2007\/82012","article-title":"Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with glivec (imatinib mesylate, Gleevec, STI571)","volume":"2007","author":"Pinder","year":"2007","journal-title":"Sarcoma"},{"key":"10.1093\/annonc\/mdq715_bb0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2710.2009.01035.x","article-title":"Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia","volume":"34","author":"Al-Kali","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1093\/annonc\/mdq715_bb0050","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdq715_bb0055","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/annonc\/mdf304","article-title":"Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase","volume":"13","author":"Vora","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq715_bb0060","first-page":"743","article-title":"Drug-induced nephrotoxicity","volume":"78","author":"Naughton","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1093\/annonc\/mdq715_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","article-title":"Renal failure associated with tyrosine kinase inhibitors\u2014case report and review of the literature","volume":"34","author":"Gafter-Gvili","year":"2010","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdq715_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-009-0109-x","article-title":"Renal toxicity of targeted therapies","volume":"4","author":"Kelly","year":"2009","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdq715_bb0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0002-9440(10)63651-6","article-title":"Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury","volume":"163","author":"Takikita-Suzuki","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdq715_bb0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq715_bb0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq715_bb0090","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq715_bb0095","first-page":"S1","article-title":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1093\/annonc\/mdq715_bb0100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1681\/ASN.2004070539","article-title":"Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000","volume":"16","author":"Coresh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1093\/annonc\/mdq715_bb0105","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdq715_bb0110","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mdq715_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1515\/CCLM.2009.263","article-title":"Glomerular filtration rate measurement and prediction equations","volume":"47","author":"Soares","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1093\/annonc\/mdq715_bb0120","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1093\/annonc\/mdq715_bb0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdq715_bb0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/aje\/kwp151","article-title":"Defining incident chronic kidney disease in the research setting: the ARIC Study","volume":"170","author":"Bash","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1093\/annonc\/mdq715_bb0135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq715_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq715_bb0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"10.1093\/annonc\/mdq715_bb0150","first-page":"984","article-title":"National Comprehensive Cancer Network\u00ae (NCCN) Practice Guidelines in Oncology\u2122: Chronic Myelogenous Leukemia Version 2.2010","volume":"7","author":"O'Brien","year":"2009","journal-title":"JNCCN"},{"key":"10.1093\/annonc\/mdq715_bb0155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/path.2111","article-title":"Renal ageing","volume":"211","author":"Martin","year":"2007","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdq715_bb0160","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/sj.ki.5002374","article-title":"Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study","volume":"72","author":"Wetzels","year":"2007","journal-title":"Kidney Int"},{"key":"10.1093\/annonc\/mdq715_bb0165","doi-asserted-by":"crossref","first-page":"C153","DOI":"10.1152\/ajpcell.00120.2007","article-title":"IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium","volume":"294","author":"Lechner","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1093\/annonc\/mdq715_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10637-005-4543-z","article-title":"Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma","volume":"24","author":"Vuky","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdq715_bb0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08860220903391226","article-title":"Acute renal failure under dasatinib therapy","volume":"32","author":"Ozkurt","year":"2010","journal-title":"Ren Fail"},{"key":"10.1093\/annonc\/mdq715_bb0180","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ki.1985.205","article-title":"Limitations of creatinine as a filtration marker in glomerulopathic patients","volume":"28","author":"Shemesh","year":"1985","journal-title":"Kidney Int"},{"key":"10.1093\/annonc\/mdq715_bb0185","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq715_bb0190","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1172\/JCI34252","article-title":"Structural reengineering of imatinib to decrease cardiac risk in cancer therapy","volume":"117","author":"Demetri","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdq715_bb0195","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdq715_bb0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq715_bb0205","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341938353X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341938353X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/9\/2073\/557842\/mdq715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:12:50Z","timestamp":1624684370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341938353X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S092375341938353X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq715","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}